Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/
New analysis of European CKD non-dialysis patient chart data reveals notable differences in nephrologists’ use of renal therapies, including SGLT2
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be
The new addition ties Spherix’s unique approach to syndicated research to a highly dynamic market, filling the white space for
From: Endpoints News By: Beth Snyder Bulik Five months after the approval of Biogen’s Aduhelm, the bad news just
From: Multiple Sclerosis News Today By: Marisa Wexler MS Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for
